192 related articles for article (PubMed ID: 26964498)
1. Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases.
Patel SP; Vaishya R; Patel A; Agrahari V; Pal D; Mitra AK
J Microencapsul; 2016; 33(2):103-13. PubMed ID: 26964498
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles in thermosensitive gel based composite nanosystem for ocular diseases.
Agrahari V; Patel SP; Dhall N; Aulgur Z; Thukral S; Yang X; Conley R; Mitra AK
Drug Deliv Transl Res; 2018 Apr; 8(2):422-435. PubMed ID: 29181835
[TBL] [Abstract][Full Text] [Related]
3. Composite Nanoformulation Therapeutics for Long-Term Ocular Delivery of Macromolecules.
Agrahari V; Agrahari V; Hung WT; Christenson LK; Mitra AK
Mol Pharm; 2016 Sep; 13(9):2912-22. PubMed ID: 26828415
[TBL] [Abstract][Full Text] [Related]
4. Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery.
Patel SP; Vaishya R; Pal D; Mitra AK
AAPS PharmSciTech; 2015 Apr; 16(2):327-43. PubMed ID: 25319053
[TBL] [Abstract][Full Text] [Related]
5. Novel Random Triblock Copolymers for Sustained Delivery of Macromolecules for the Treatment of Ocular Diseases.
Ngatuni MJ; Trinh HM; Pal D; Mitra AK
AAPS PharmSciTech; 2018 Nov; 19(8):3871-3885. PubMed ID: 30306402
[TBL] [Abstract][Full Text] [Related]
6. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics.
Patel SP; Vaishya R; Mishra GP; Tamboli V; Pal D; Mitra AK
J Drug Deliv; 2014; 2014():401747. PubMed ID: 25045540
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate.
Yang X; Trinh HM; Agrahari V; Sheng Y; Pal D; Mitra AK
AAPS PharmSciTech; 2016 Apr; 17(2):294-306. PubMed ID: 26085051
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Intracameral Pentablock Copolymer Thermosensitive Gel for Sustained Drug Delivery to the Anterior Chamber of the Eye.
Schaefer E; Smith SM; Salmon J; Abbaraju S; Amin R; Weiss S; Grau U; Velagaleti P; Gilger B
J Ocul Pharmacol Ther; 2017 Jun; 33(5):353-360. PubMed ID: 28300477
[TBL] [Abstract][Full Text] [Related]
9. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs.
Ye Q; Asherman J; Stevenson M; Brownson E; Katre NV
J Control Release; 2000 Feb; 64(1-3):155-66. PubMed ID: 10640654
[TBL] [Abstract][Full Text] [Related]
10. Extended release microparticle-in-gel formulation of octreotide: Effect of polymer type on acylation of peptide during in vitro release.
Vaishya RD; Mandal A; Patel S; Mitra AK
Int J Pharm; 2015 Dec; 496(2):676-88. PubMed ID: 26561725
[TBL] [Abstract][Full Text] [Related]
11. Long-term delivery of protein therapeutics.
Vaishya R; Khurana V; Patel S; Mitra AK
Expert Opin Drug Deliv; 2015 Mar; 12(3):415-40. PubMed ID: 25251334
[TBL] [Abstract][Full Text] [Related]
12. In-situ forming gels containing fluorometholone-loaded polymeric nanoparticles for ocular inflammatory conditions.
Gonzalez-Pizarro R; Carvajal-Vidal P; Halbault Bellowa L; Calpena AC; Espina M; García ML
Colloids Surf B Biointerfaces; 2019 Mar; 175():365-374. PubMed ID: 30554015
[TBL] [Abstract][Full Text] [Related]
13. Drug release from pH-responsive thermogelling pentablock copolymers.
Determan MD; Cox JP; Mallapragada SK
J Biomed Mater Res A; 2007 May; 81(2):326-33. PubMed ID: 17120218
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
Bisht R; Jaiswal JK; Rupenthal ID
Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery.
Mahlumba P; Choonara YE; Kumar P; du Toit LC; Pillay V
Molecules; 2016 Jul; 21(8):. PubMed ID: 27483234
[TBL] [Abstract][Full Text] [Related]
16. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.
Yasin MN; Svirskis D; Seyfoddin A; Rupenthal ID
J Control Release; 2014 Dec; 196():208-21. PubMed ID: 25307997
[TBL] [Abstract][Full Text] [Related]
17. Drug delivery to the posterior segment of the eye.
Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
[TBL] [Abstract][Full Text] [Related]
18. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study.
Singh J; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522
[TBL] [Abstract][Full Text] [Related]
19. Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders.
Egusquiaguirre SP; Manguán-García C; Pintado-Berninches L; Iarriccio L; Carbajo D; Albericio F; Royo M; Pedraz JL; Hernández RM; Perona R; Igartua M
Eur J Pharm Biopharm; 2015 Apr; 91():91-102. PubMed ID: 25660910
[TBL] [Abstract][Full Text] [Related]
20. Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins.
Rizwan SB; Boyd BJ; Rades T; Hook S
Expert Opin Drug Deliv; 2010 Oct; 7(10):1133-44. PubMed ID: 20858165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
